JP2020518556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518556A5 JP2020518556A5 JP2019555219A JP2019555219A JP2020518556A5 JP 2020518556 A5 JP2020518556 A5 JP 2020518556A5 JP 2019555219 A JP2019555219 A JP 2019555219A JP 2019555219 A JP2019555219 A JP 2019555219A JP 2020518556 A5 JP2020518556 A5 JP 2020518556A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- amino acid
- disorders
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023051477A JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
| JP2025037548A JP2025090703A (ja) | 2017-05-04 | 2025-03-10 | 糖尿病の処置のためのペプチド |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17169500 | 2017-05-04 | ||
| EP17169500.0 | 2017-05-04 | ||
| PCT/EP2018/061547 WO2018202870A1 (en) | 2017-05-04 | 2018-05-04 | Peptides for treatment of diabetes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051477A Division JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518556A JP2020518556A (ja) | 2020-06-25 |
| JP2020518556A5 true JP2020518556A5 (https=) | 2021-06-17 |
Family
ID=58671461
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555219A Pending JP2020518556A (ja) | 2017-05-04 | 2018-05-04 | 糖尿病の処置のためのペプチド |
| JP2023051477A Ceased JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
| JP2025037548A Pending JP2025090703A (ja) | 2017-05-04 | 2025-03-10 | 糖尿病の処置のためのペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023051477A Ceased JP2023082076A (ja) | 2017-05-04 | 2023-03-28 | 糖尿病の処置のためのペプチド |
| JP2025037548A Pending JP2025090703A (ja) | 2017-05-04 | 2025-03-10 | 糖尿病の処置のためのペプチド |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10815283B2 (https=) |
| EP (1) | EP3618845B1 (https=) |
| JP (3) | JP2020518556A (https=) |
| KR (1) | KR102700014B1 (https=) |
| CN (1) | CN110545834B (https=) |
| AU (1) | AU2018262805B2 (https=) |
| BR (1) | BR112019021886A2 (https=) |
| CA (1) | CA3061935A1 (https=) |
| DK (1) | DK3618845T3 (https=) |
| EA (1) | EA201992562A1 (https=) |
| ES (1) | ES2857749T3 (https=) |
| IL (1) | IL270199B2 (https=) |
| MX (1) | MX2019013096A (https=) |
| PL (1) | PL3618845T3 (https=) |
| SG (1) | SG11201908513RA (https=) |
| WO (1) | WO2018202870A1 (https=) |
| ZA (1) | ZA201905891B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210088583A (ko) * | 2018-11-07 | 2021-07-14 | 폴리쿰 에이비 | 당뇨병 치료를 위한 펩타이드 단편 |
| US20220273765A1 (en) | 2019-04-24 | 2022-09-01 | Follicum Ab | Topical formulation |
| KR102816261B1 (ko) * | 2022-03-24 | 2025-06-05 | (주)케어젠 | 항당뇨 활성을 갖는 펩타이드 복합체 및 이의 용도 |
| CA3251755A1 (en) * | 2022-05-13 | 2023-11-16 | Coegin Pharma Ab | VASCULARIZING AGENTS |
| WO2023218095A1 (en) * | 2022-05-13 | 2023-11-16 | Coegin Pharma Ab | Agents for stimulating tissue regeneration |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6482410B1 (en) | 1994-09-16 | 2002-11-19 | The Scripps Research Institute | Cytotactin derivatives that stimulate attachment and neurite outgrowth, and methods of making same |
| WO1999015904A1 (en) | 1997-09-26 | 1999-04-01 | University Of Washington | Methods and compositions for diagnosing renal pathologies |
| US6551990B2 (en) | 1998-12-07 | 2003-04-22 | University Of Washington | Methods of inhibiting ectopic calcification |
| DE60131525T2 (de) * | 2000-03-23 | 2008-09-25 | Glaxo Group Ltd., Greenford | Verfahren zum screening von inhibitoren für osteopontin |
| CN1439020A (zh) | 2000-06-13 | 2003-08-27 | 儿童医学中心公司 | 生物合成的溶瘤分子及其用途 |
| MXPA03010327A (es) | 2001-05-17 | 2004-02-17 | Applied Research Systems | USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS. |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| AU2003239589A1 (en) | 2002-05-24 | 2003-12-12 | Schering-Plough Ltd. | Eta-1 gene and methods for use |
| EP1637159A4 (en) * | 2003-05-23 | 2009-01-21 | Immuno Biological Lab Co Ltd | IMMUNOCOMPETENT CELL ACTIVATION INHIBITOR AND USE THEREOF |
| WO2008086449A2 (en) | 2007-01-09 | 2008-07-17 | Oregon Health & Science University | Synthetic osteopontin peptides and methods of use |
| AU2008223817A1 (en) | 2007-03-02 | 2008-09-12 | National University Of Ireland, Galway | Osteopontin for the prediction and treatment of cardiovascular diseases |
| EP2140268A4 (en) | 2007-04-17 | 2011-05-04 | Pfizer | METHOD FOR CONTROLLING GLUCOSE TREATMENT AND INSULIN SENSITIVITY |
| CN101293916A (zh) | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及用途 |
| EP2215246B1 (en) * | 2007-10-31 | 2015-01-07 | MedImmune, LLC | Protein scaffolds |
| CN101215324B (zh) * | 2007-12-26 | 2010-11-24 | 吉林大学 | 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用 |
| WO2011058182A1 (en) | 2009-11-13 | 2011-05-19 | National University Of Ireland, Galway | Osteopontin-conditioned medium for the treatment of vascular diseases |
| GB2493540A (en) | 2011-08-10 | 2013-02-13 | Follicum Ab | Agents for stimulating hair growth in mammals |
| US20150190460A1 (en) | 2012-07-20 | 2015-07-09 | Forsyth Dental Infirmary For Children (D/B/A The Forsyth Institute) | Osteopontin peptide fragments for use in suppression or prevention of tumor growth |
| GB201406989D0 (en) * | 2014-04-17 | 2014-06-04 | Follicum Ab | Novel treatments |
| JP7091255B2 (ja) | 2016-05-06 | 2022-06-27 | アイオニス・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１受容体リガンド部分コンジュゲート化オリゴヌクレオチドおよびその使用 |
-
2018
- 2018-05-04 DK DK18721806.0T patent/DK3618845T3/da active
- 2018-05-04 EA EA201992562A patent/EA201992562A1/ru unknown
- 2018-05-04 AU AU2018262805A patent/AU2018262805B2/en active Active
- 2018-05-04 KR KR1020197027946A patent/KR102700014B1/ko active Active
- 2018-05-04 ES ES18721806T patent/ES2857749T3/es active Active
- 2018-05-04 JP JP2019555219A patent/JP2020518556A/ja active Pending
- 2018-05-04 IL IL270199A patent/IL270199B2/en unknown
- 2018-05-04 WO PCT/EP2018/061547 patent/WO2018202870A1/en not_active Ceased
- 2018-05-04 EP EP18721806.0A patent/EP3618845B1/en active Active
- 2018-05-04 CN CN201880026723.5A patent/CN110545834B/zh active Active
- 2018-05-04 CA CA3061935A patent/CA3061935A1/en active Pending
- 2018-05-04 MX MX2019013096A patent/MX2019013096A/es unknown
- 2018-05-04 BR BR112019021886-6A patent/BR112019021886A2/pt unknown
- 2018-05-04 PL PL18721806T patent/PL3618845T3/pl unknown
- 2018-05-04 SG SG11201908513R patent/SG11201908513RA/en unknown
-
2019
- 2019-09-06 ZA ZA2019/05891A patent/ZA201905891B/en unknown
- 2019-10-29 US US16/666,960 patent/US10815283B2/en active Active
-
2020
- 2020-09-16 US US17/022,526 patent/US20210009648A1/en not_active Abandoned
-
2023
- 2023-03-28 JP JP2023051477A patent/JP2023082076A/ja not_active Ceased
-
2025
- 2025-03-10 JP JP2025037548A patent/JP2025090703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518556A5 (https=) | ||
| Mariam et al. | Glucagon‐like peptide agonists: a prospective review | |
| Zheng et al. | Glucagon-like peptide-1 receptor: mechanisms and advances in therapy | |
| Iorga et al. | Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect | |
| Madsen et al. | Structure− activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness | |
| JP3149958B2 (ja) | Ｇｌｐ―１誘導体 | |
| Röhrborn et al. | DPP4 in diabetes | |
| Okerson et al. | The cardiovascular effects of GLP‐1 receptor agonists | |
| Coulter-Parkhill et al. | Therapeutic potential of peptides derived from animal venoms: current views and emerging drugs for diabetes | |
| Choe et al. | Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists | |
| Xiao et al. | Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo | |
| Pabreja et al. | Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP‐1R activation | |
| TW201247702A (en) | Use of acylated glucagon analogues | |
| CN106459170B (zh) | 衍生自毒蜥外泌肽-4的glp-1/胰高血糖素受体双重激动剂 | |
| Tomlinson et al. | An overview of new GLP-1 receptor agonists for type 2 diabetes | |
| Lotfy et al. | Medicinal chemistry and applications of incretins and DPP-4 inhibitors in the treatment of type 2 diabetes mellitus | |
| Gallwitz | GLP-1 agonists and dipeptidyl-peptidase IV inhibitors | |
| CN104736558A (zh) | 用于治疗代谢综合征的融合蛋白 | |
| McIntosh et al. | Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus | |
| Li et al. | Recent clinical advances of glucokinase activators in the treatment of diabetes mellitus type 2 | |
| CN106279400A (zh) | P8降糖肽的设计及其用途 | |
| Claus et al. | Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes | |
| Heo et al. | Glucagon-like peptide-1 and its cardiovascular effects | |
| Rosen et al. | GLP-1 receptor agonists | |
| Zarei et al. | The expanding role of semaglutide: beyond glycemic control |